Glycolytic enzymes as autoantigens


A lot of work has been done to attest the prevalence of glycolytic enzymes, and in particular of enolase, as autoantigens in autoimmune disorders. Antibodies to the isoform alpha (and to a lesser extent to the isoform gamma) of the enzyme enolase have been reported in a variety of immunological diseases (table 1), and yet the prevalence of these autoantibodies in ME/CFS has not been measured, so far, as has been recently pointed out (Sotzny F et al. 2018).

Anti-enolase Abs in ME/CFS

Recently a role for anti-gamma enolase Abs has been proposed in post-treatment Lyme disease syndrome: it has been postulated that sequence similitude between Borrelia own enolase and human enolase might be the cause of cross-reactive autoantibodies (Maccallini P et al. 2018).  A similar pathogenic role for anti-enolase antibodies has been previously proposed in PANDAS (Dale, et al., 2006) and in rheumatoid arthritis (Lee JY et al 2015), with the putative triggering bacterial enolases belonging to Streptococcus pyogenes and to Porphyromonas gingivalis, respectively. Besides molecular mimicry, a pathological increase in glycolytic enzymes expression has been proposed as the cause for the rise of autoantibodies to these proteins (Chang X et Wei Chao 2011). Both these triggering events are theoretically possible in ME/CFS, given that this disease is initiated by an infectious event in many cases (Hickie I et al. 2006) and an increase in glycolysis has been described in peripheral white blood cells from ME/CFS patients (Lawson N et al. 2016). Although autoimmunity against enolase is present in many autoimmune diseases, it seems that different autoepitopes are involved in different diseases (see epitopes in red, in table 2). So if we found autoantibodies to enolase in ME/CFS, we could perhaps find a specific autoepitope useful for diagnostic purposes.

Table 1. Antibodies to the three isoforms of enolase in autoimmune diseases (table by Paolo Maccallini).

Anti-enolase Abs and diseases

The first report of anti-enolase antibodies was in 1991. One woman with hyperthyroidism and vague muscular pain and another one with Raynaud’s phenomenon, both had serum reactive to all the three subunits of enolase (Rattner, et al., 1991). During the following years autoantibodies against enolase have been reported in systemic autoimmune diseases, such as Behçet’s disease (Lee, et al., 2003 ), rheumatoid arthritis (Saulot, et al., 2002), systemic lupus erythematosus, and systemic sclerosis (Pratesi, et al., 2000). They have been reported in organ specific autoimmune diseases too, such as cancer related retinopathy (Adamus, et al., 1996), autoimmune hepatitis, primary biliary cirrhosis (Akisawa, et al., 1997), hypophysitis (O’Dwyer, et al., 2002), discoid lupus erythematosus (Gitlits, et al., 1997), idiopathic juvenile arthritis, Crohn’s disease (Pontillo, et al., 2011); and in brain pathologies as Hashimoto’s encephalopathy (Fujii A1, et al., 2005), multiple sclerosis (Forooghian, et al., 2007), encephalitis lethargica (Dale, et al., 2004), PANDAS, Sydenham’s chorea (Dale, et al., 2006), and obsessive-compulsive disorder in adults (Nicholson, et al., 2012). Anti-enolase autoantibodies have been detected also in diseases of unknown etiology, such as Buerger’s disease and atherosclerosis (Witkowska, et al., 2005). Prevalence of anti-enolase antibodies in these diseases is reviewed in Table 1. P values are reported when available.

tabella 2.png
Table 2. Autoepitopes on alpha enolase primary structure in red (table by Paolo Maccallini).


Consider supporting this website with a donation.




Un pensiero su “Glycolytic enzymes as autoantigens

  1. Several of diseases in the list are triggered by Borelia specie and other zoonic stealth pathogens (many unclassified).
    So why focus on the symptoms but on the real cause of the symptoms. You know at times it is worth to step back and look at the big picture and connect the dots.
    And then we have this, “….Abs has been proposed in post-treatment Lyme disease syndrome..”. There is not PLDS there is chronic lyme borreliosis. Meaning, Borrelia does not die and a large number of the population (quantification of the exact number is a guess at most) reacts to the biotoxines with an autoimmune suppression. Again the politics dictates the wording behind the science one more time.

    Mi piace


Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:


Stai commentando usando il tuo account Chiudi sessione /  Modifica )

Google+ photo

Stai commentando usando il tuo account Google+. Chiudi sessione /  Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione /  Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione /  Modifica )

Connessione a %s...